1Gurumm hy P, Borra SK, Yeruva RK, et al. Estimation of ischemia modi- fied albumin (IMA) levels in patients with acute coronary syndrome[J]. Indian J Clin Biochem,2014,29(3):367- 371.
2Loukas M, Bilinsky S, Bilinsky E, et al. The clinical anatomy of the coro- nary collateral circulation [ J ]. C lin ?mat, 2009,22 : 146 - 160.
3Traupe T, Gloekler S, de Marchi SF, et al. Assessment of the hmnan coronary collateral circulation[J]. Circulation,2010,122:1210- 1220.
4Mouquet F, Cuilleret F, Susen S, et al. Metabolic syndrome and collateral vessd formation in patients with documented occluded coronary arteries: as- sociation with hyperglycaemla, insulin-resistance, adiponeetion and plas- minogen activator inhibitor-1 [ J]. Eur Heart J, 2009,30: 840 - 849.
5Kim J, Lee JH, Pm'k HS, et al. Syndecan-4 regulates platelet-derived growth factor-mediated MAP kinase activation by altering intracellular reac- tive oxygen species [ J]. FEBS Left, 2008,582 (18) : 2725 - 2730.
7Kim JG, Kim EO, Jeong BR, et al MCF-7 human breast cancer cells[J]. Visfatin stimulates proliferation of Mol Cells,2010.30(4) :341 - 345.
同被引文献15
1Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatclet therapy [J]. CircJ, 2014, 78 (3): 679-684.
2LOpez de Landache IE, Braceras Izaguirre L, Echeto Garcia A, et al. Efficiency in the prescription of drugs. Impact of a health policy: automatic change to prescription by active ingredient [ J ]. Rev Enferm, 2013, 36 (11): 49-52.
3Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy - the PEARL randomized cross - over study [ J ]. Eur J Pharmacol, 2014, 725: 18-22.
